Longterm Effects of Rituximab on B Cell Counts and Autoantibody Production in Rheumatoid Arthritis: Use of High-sensitivity Flow Cytometry for More Sensitive Assessment of B Cell Depletion

REFERENCES

1. 1.↵
   1. Smolen JS,
   2. Keystone EC,
   3. Emery P,
   4. Breedveld FC,
   5. Betteridge N,
   6. Burmester GR,
   7. et al.

   Consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 2007;66:143–50.

   OpenUrlAbstract/FREE Full Text
2. 2.↵
   1. Cohen SB

   . Targeting the B cell in rheumatoid arthritis. Best Pract Res Clin Rheumatol 2010;24:553–63.

   OpenUrlCrossRefPubMed
3. 3.↵
   1. Keystone E,
   2. Emery P,
   3. Peterfy CG,
   4. Tak PP,
   5. Cohen S,
   6. Genovese MC,
   7. et al.

   Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies. Ann Rheum Dis 2009;68:216–21.

   OpenUrlAbstract/FREE Full Text
4. 4.↵
   1. Buch MH,
   2. Smolen JS,
   3. Betteridge N,
   4. Breedveld FC,
   5. Burmester G,
   6. Dorner T,
   7. et al.

   Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 2011;70:909–20.

   OpenUrlAbstract/FREE Full Text
5. 5.↵
   1. Thurlings RM,
   2. Vos K,
   3. Wijbrandts CA,
   4. Zwinderman AH,
   5. Gerlag DM,
   6. Tak PP

   . Synovial tissue response to rituximab: Mechanism of action and identification of biomarkers of response. Ann Rheum Dis 2008;67:917–25.

   OpenUrlAbstract/FREE Full Text
6. 6.↵
   1. Cambridge G,
   2. Leandro MJ,
   3. Edwards JC,
   4. Ehrenstein MR,
   5. Salden M,
   6. Bodman-Smith M,
   7. et al.

   Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum 2003;48:2146–54.

   OpenUrlCrossRefPubMed
7. 7.↵
   1. Cambridge G,
   2. Stohl W,
   3. Leandro MJ,
   4. Migone TS,
   5. Hilbert DM,
   6. Edwards JC

   . Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: Relationships with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum 2006;54:723–32.

   OpenUrlCrossRefPubMed
8. 8.↵
   1. Benucci M,
   2. Manfredi M,
   3. Puttini PS,
   4. Atzeni F

   . Predictive factors of response to rituximab therapy in rheumatoid arthritis: What do we know today? Autoimmun Rev 2010;9:801–3.

   OpenUrlCrossRefPubMed
9. 9.↵
   1. Quartuccio L,
   2. Fabris M,
   3. Salvin S,
   4. Atzeni F,
   5. Saracco M,
   6. Benucci M,
   7. et al.

   Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis. Rheumatology 2009;48:1557–9.

   OpenUrlAbstract/FREE Full Text
10. 10.↵
    1. Szodoray P,
    2. Szabó Z,
    3. Kapitány A,
    4. Gyetvai A,
    5. Lakos G,
    6. Szántó S,
    7. et al.

    Anti-citrullinated protein/peptide autoantibodies in association with genetic and environmental factors as indicators of disease outcome in rheumatoid arthritis. Autoimmun Rev 2010;9:140–3.

    OpenUrlCrossRefPubMed
11. 11.↵
    1. Anolik JH,
    2. Campbell D,
    3. Felgar RE,
    4. Young F,
    5. Sanz I,
    6. Rosenblatt J,
    7. et al.

    The relationship of Fc gamma RIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum 2003;48:455–9.

    OpenUrlCrossRefPubMed
12. 12.↵
    1. Dorner T,
    2. Kinnman N,
    3. Tak PP

    . Targeting B cells in immune-mediated inflammatory disease: A comprehensive review of mechanisms of action and identification of biomarkers. Pharmacol Ther 2010;125:464–75.

    OpenUrlCrossRefPubMed
13. 13.↵
    1. Sellam J,
    2. Hendel-Chavez H,
    3. Rouanet S,
    4. Abbed K,
    5. Combe B,
    6. Le Loët X,
    7. et al.

    B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: A six-month, national, multicenter, open-label study. Arthritis Rheum 2011;63:933–8.

    OpenUrlCrossRefPubMed
14. 14.↵
    1. Belmonte Serrano MA,
    2. Pincus T

    . Comment on: Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis. Rheumatology 2010;49:1795–6.

    OpenUrlFREE Full Text
15. 15.↵
    1. Levesque MC,
    2. St. Clair EW

    . B cell-directed therapies for autoimmune disease and correlates of disease response and relapse. J Allergy Clin Immunol 2008;121:13–21; quiz 22–13.

    OpenUrlCrossRefPubMed
16. 16.↵
    1. Vital EM,
    2. Dass S,
    3. Rawstron AC,
    4. Buch MH,
    5. Goëb V,
    6. Henshaw K,
    7. et al.

    Management of nonresponse to rituximab in rheumatoid arthritis: Predictors and outcome of re-treatment. Arthritis Rheum 2010;62:1273–9.

    OpenUrlCrossRefPubMed
17. 17.↵
    1. Vital EM,
    2. Dass S,
    3. Buch MH,
    4. Rawstron AC,
    5. Ponchel F,
    6. McGonagle D,
    7. et al.

    Re-treatment of rheumatoid arthritis patients who were initial nonresponders to rituximab: comment on the article by Thurlings et al. Arthritis Rheum 2009;60:1867.

    OpenUrlPubMed
18. 18.↵
    1. Dass S,
    2. Rawstron AC,
    3. Vital EM,
    4. Henshaw K,
    5. McGonagle D,
    6. Emery P

    . Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis. Arthritis Rheum 2008;58:2993–9.

    OpenUrlCrossRefPubMed
19. 19.↵
    1. Breedveld F,
    2. Agarwal S,
    3. Yin M,
    4. Ren S,
    5. Li NF,
    6. Shaw TM,
    7. et al.

    Rituximab pharmacokinetics in patients with rheumatoid arthritis: B-cell levels do not correlate with clinical response. J Clin Pharmacol 2007;47:1119–28.

    OpenUrlCrossRefPubMed
20. 20.↵
    1. Fan PT,
    2. Yu DT,
    3. Clements PJ,
    4. Fowlston S,
    5. Eisman J,
    6. Bluestone R

    . Effect of corticosteroids on the human immune response: Comparison of one and three daily 1 gm intravenous pulses of methylprednisolone. J Lab Clin Med 1978;91:625–34.

    OpenUrlPubMed
21. 21.↵
    1. Kaleem Z,
    2. White G,
    3. Vollmer RT

    . Critical analysis and diagnostic usefulness of limited immunophenotyping of B-cell non-Hodgkin lymphomas by flow cytometry. Am J Clin Pathol 2001;115:136–42.

    OpenUrlAbstract/FREE Full Text
22. 22.↵
    1. Shao H,
    2. Yuan CM,
    3. Xi L,
    4. Raffeld M,
    5. Morris JC,
    6. Janik JE,
    7. et al.

    Minimal residual disease detection by flow cytometry in adult T-cell leukemia/lymphoma. Am J Clin Pathol 2010;133:592–601.

    OpenUrlAbstract/FREE Full Text
23. 23.↵
    1. Finckh A,
    2. Ciurea A,
    3. Brulhart L,
    4. Möller B,
    5. Walker UA,
    6. Courvoisier D,
    7. et al.

    Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent? Ann Rheum Dis 2010;69:387–93.

    OpenUrlAbstract/FREE Full Text
24. 24.↵
    1. Teng YK,
    2. Tekstra J,
    3. Breedveld FC,
    4. Lafeber F,
    5. Bijlsma JW,
    6. van Laar JM

    . Rituximab fixed retreatment versus on-demand retreatment in refractory rheumatoid arthritis: Comparison of two B cell depleting treatment strategies. Ann Rheum Dis 2009;68:1075–7.

    OpenUrlFREE Full Text